Fyi, Comfort is added into MSCI small cap indexes list. In summary it is a recognition to Comfort as MSCI select stocks that have high liquidity and represents the underlying equity market well. Funds / Investment Firms / Investors evaluate MSCI stocks in weighting of small cap stocks as part of diversified investment portfolio as it provide exposure which offer faster growth, good risk-adjusted returns which has different virtues with larger cap stocks. Hope this helps.
Something to think about: Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer - that she learned of the results on Sunday just after 1pm ..... vaccine phase 3 preliminary information was announced on Monday... CEO Pfizer sold US5.66 mln on Monday and also Pfizer Senior Management.... A Pfizer spokesperson said of CEO Pfizer stock sale, the sale was part of a predetermined plan created in August....
The Dow is in negative territory today. The Pfizer news is really short lived. When reality sets in, market knows that the vaccine is far from reachable to the masses to make it matter the most for the economy. Oil and gas stock also failed to rebound, all in negative territory today. This is a fact, taken into consideration that Pfizer is going to supply the vaccine to the US first before the rest of the world when it is going to be available, it still fail to provide any positive vibe to the US economy. It is really foolish to think that the Pfizer vaccine will reach this country before the US. The news really has not material impact to the other section of economy except for pandemic related stock.
What this tell us when it come to investing ? Simple, the virus is not going anywhere anytime soon. In fact, it is raging wildly in the US, post election.
Moderna Inc said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help determine the vaccine's efficacy.
Moderna said the information is being prepared for submission to the trial's independent data safety monitoring board, which will look at the results and make a recommendation. It did not say when it plans to release the efficacy data.
The company said in a news release that it has seen a significant increase in the number of COVID-19 cases among trial participants as infection rates have surged around the United States.
Due to the spike in cases, the analysis will cover substantially more than 53 infections, which had been the targeted trigger point for the first analysis.
The company said the trial remains blinded, so neither it nor study investigators know which participants received the vaccine or a placebo. The vaccine will be deemed a success if the overwhelming majority of those infected had received a placebo, once the monitoring board looks at the early results.
Earlier in the day, Dr. Anthony Fauci, the top U.S. infectious disease expert, said Moderna could have the data from anywhere between "a couple of days" to "a little more than a week."
A high degree of effectiveness would make sense as it is "almost identical" to Pfizer Inc's experimental vaccine, Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said at a conference organized by the Financial Times.
"It may not be 95%, it might be 90%, or 96%, or 89%, but it is going to be up there," he said.
Pfizer on Monday said its COVID-19 vaccine was more than 90% effective based on interim trial results, significantly higher than the at least 50% efficacy regulators are looking for.
Moderna, which uses a similar messenger RNA technology as Pfizer, said earlier on Wednesday that its November timeline for initial data was on track.
It did not respond to a Reuters request for comment on when it would disclose the data.
The company would still have to wait for two-month follow-up safety data required by the U.S. Food and Drug Administration, which it expects to have in the second half of this month, before applying for U.S. emergency use authorization.
There are no vaccines that have gained global approval yet, although a handful, including Moderna's, are in late-stage studies.
Moderna's shares closed up 8.4% at $82.44 and rose to $83.85 in extended trading
Another vaccine results coming out soon. Beware to all glove lover and shareholders.
Very low volume for all today. It is not going to sit still forever. Time to add up. Opportunity is now. After the Vaccine hype is over, funds will come back to Gloves counters.. AS NOTHING WILL CHANGE TOMORROW OR THE NEXT 6 MONTHS.
we are the one to buy and resposible for our gain/loss, nothing to do with you. Don't keep coming here to talk something bad. We like to buy and hold, what's wrong with you. how much you are in the comfort, me more than 100k also don't care...what are you worrying
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
jhnwck
33 posts
Posted by jhnwck > 2020-11-11 11:40 | Report Abuse
https://app2.msci.com/eqb/gimi/smallcap/MSCI_Nov20_SCPublicList.pdf
Fyi, Comfort is added into MSCI small cap indexes list. In summary it is a recognition to Comfort as MSCI select stocks that have high liquidity and represents the underlying equity market well. Funds / Investment Firms / Investors evaluate MSCI stocks in weighting of small cap stocks as part of diversified investment portfolio as it provide exposure which offer faster growth, good risk-adjusted returns which has different virtues with larger cap stocks. Hope this helps.